Clinical trial
Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury
NCT00326976 · Fibrex Medical Research & Development GmbH, Industry · Completed
Key facts
| NCT number | NCT00326976 |
|---|---|
| Title | Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury |
| Official title | A Multicenter, Double Blind, Randomized, Placebo Controlled Study to Measure the Effect of FX06 (a Fibrin Derived Peptide Bbeta15-42) on Ischemia Reperfusion Injury in Patients Undergoing Primary Percutaneous Coronary Intervention (PCI): The "F.I.R.E." Study |
| Lead sponsor | Fibrex Medical Research & Development GmbH, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myocardial Ischemia, Coronary Disease, Myocardial Infarction |
| Intervention type | Drug, Procedure |
| Interventions | FX06, Percutaneous coronary intervention |
| Enrollment | 234 |
| Start date | Aug 1, 2006 |
| Completion | Nov 1, 2007 |
| First posted | May 17, 2006 |
| Last update posted | Dec 4, 2007 |
| Countries | Austria, Belgium, Czechia, Denmark, Germany, Lithuania, Netherlands, Poland, Romania, Sweden, Switzerland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: